170 related articles for article (PubMed ID: 25069724)
1. Modulation, bioinformatic screening, and assessment of small molecular peptides targeting the vascular endothelial growth factor receptor.
Feng S; Zou L; Ni Q; Zhang X; Li Q; Zheng L; Xie L; Li H; Huang D
Cell Biochem Biophys; 2014 Dec; 70(3):1913-21. PubMed ID: 25069724
[TBL] [Abstract][Full Text] [Related]
2. Preparation,
Barta P; Kamaraj R; Kucharova M; Novy Z; Petrik M; Bendova K; Hajduch M; Pavek P; Trejtnar F
Bioconjug Chem; 2022 Oct; 33(10):1825-1836. PubMed ID: 36197842
[TBL] [Abstract][Full Text] [Related]
3. Novel small peptides derived from VEGF
Zhang X; Feng S; Liu J; Li Q; Zheng L; Xie L; Li H; Huang D
Sci Rep; 2017 Jun; 7(1):4278. PubMed ID: 28655913
[TBL] [Abstract][Full Text] [Related]
4. Helical peptides from VEGF and Vammin hotspots for modulating the VEGF-VEGFR interaction.
García-Aranda MI; González-López S; Santiveri CM; Gagey-Eilstein N; Reille-Seroussi M; Martín-Martínez M; Inguimbert N; Vidal M; García-López MT; Jiménez MA; González-Muñiz R; Pérez de Vega MJ
Org Biomol Chem; 2013 Mar; 11(11):1896-905. PubMed ID: 23381088
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
[TBL] [Abstract][Full Text] [Related]
6. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands.
Anisimov A; Leppänen VM; Tvorogov D; Zarkada G; Jeltsch M; Holopainen T; Kaijalainen S; Alitalo K
Sci Signal; 2013 Jul; 6(282):ra52. PubMed ID: 23821770
[TBL] [Abstract][Full Text] [Related]
7. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
[TBL] [Abstract][Full Text] [Related]
8. Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening.
Gautier B; Miteva MA; Goncalves V; Huguenot F; Coric P; Bouaziz S; Seijo B; Gaucher JF; Broutin I; Garbay C; Lesnard A; Rault S; Inguimbert N; Villoutreix BO; Vidal M
Chem Biol; 2011 Dec; 18(12):1631-9. PubMed ID: 22195565
[TBL] [Abstract][Full Text] [Related]
9. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
Li F; Jiang S; Zu Y; Lee DY; Li Z
J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors.
Levashova Z; Backer M; Hamby CV; Pizzonia J; Backer JM; Blankenberg FG
J Nucl Med; 2010 Jun; 51(6):959-66. PubMed ID: 20484434
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF.
Piossek C; Schneider-Mergener J; Schirner M; Vakalopoulou E; Germeroth L; Thierauch KH
J Biol Chem; 1999 Feb; 274(9):5612-9. PubMed ID: 10026178
[TBL] [Abstract][Full Text] [Related]
12. VEGFR Recognition Interface of a Proangiogenic VEGF-Mimetic Peptide Determined In Vitro and in the Presence of Endothelial Cells by NMR Spectroscopy.
Di Stasi R; Diana D; Capasso D; Di Gaetano S; De Rosa L; Celentano V; Isernia C; Fattorusso R; D'Andrea LD
Chemistry; 2018 Aug; 24(44):11461-11466. PubMed ID: 29799174
[TBL] [Abstract][Full Text] [Related]
13. Structure and function of vascular endothelial growth factor and its receptor system.
Park SA; Jeong MS; Ha KT; Jang SB
BMB Rep; 2018 Feb; 51(2):73-78. PubMed ID: 29397867
[TBL] [Abstract][Full Text] [Related]
14. Combined Use of Oligopeptides, Fragment Libraries, and Natural Compounds: A Comprehensive Approach To Sample the Druggability of Vascular Endothelial Growth Factor.
Bayó-Puxan N; Rodríguez-Mias R; Goldflam M; Kotev M; Ciudad S; Hipolito CJ; Varese M; Suga H; Campos-Olivas R; Barril X; Guallar V; Teixidó M; García J; Giralt E
ChemMedChem; 2016 Apr; 11(8):928-39. PubMed ID: 26553526
[TBL] [Abstract][Full Text] [Related]
15. Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A.
Markovic-Mueller S; Stuttfeld E; Asthana M; Weinert T; Bliven S; Goldie KN; Kisko K; Capitani G; Ballmer-Hofer K
Structure; 2017 Feb; 25(2):341-352. PubMed ID: 28111021
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
17. Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library.
Shi LF; Wu Y; Li CY
J Gynecol Oncol; 2015 Oct; 26(4):327-35. PubMed ID: 26197772
[TBL] [Abstract][Full Text] [Related]
18. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
[TBL] [Abstract][Full Text] [Related]
19. Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein.
Chandrasekaran V; Ambati J; Ambati BK; Taylor EW
J Mol Graph Model; 2007 Nov; 26(4):775-82. PubMed ID: 17560152
[TBL] [Abstract][Full Text] [Related]
20. Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast.
Khan GA; Girish GV; Lala N; Di Guglielmo GM; Lala PK
Mol Endocrinol; 2011 Aug; 25(8):1431-43. PubMed ID: 21659473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
